Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-07-09 Declaration of Voting R…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juin 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers". It provides a table detailing the total number of shares and voting rights as of a specific date (June 30, 2025), referencing French regulatory articles (Code de commerce and AMF General Regulation). This type of mandatory disclosure regarding the total voting rights and share capital structure is a specific regulatory filing requirement in France. It does not fit the definition of an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a general announcement of a report (RPA). It is a specific regulatory disclosure concerning capital structure and voting rights. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the number of shares and voting rights, although it is a periodic disclosure rather than a transaction announcement. However, given the highly specific nature of the content (total voting rights disclosure mandated by specific articles), and lacking a dedicated code for 'Total Voting Rights Disclosure', it must be classified based on the closest category related to share capital structure, which is SHA. Alternatively, if this is considered a routine regulatory filing that doesn't fit elsewhere, RNS (Regulatory Filings) could be used. Since it is a specific, recurring disclosure about the capital base, SHA is more precise than the general RNS fallback.
2025-07-09 French
Sanofi: Information concerning the total number of voting rights and shares - June 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns the 'total number of voting rights and shares' pursuant to French commercial code and AMF regulations. It provides a table detailing the total number of issued shares and voting rights as of a specific date (30 June 2025). This type of mandatory disclosure regarding share capital structure and voting power is a specific regulatory filing. While it relates to capital, it is not a general financing update (CAP) or a share issue announcement (SHA). It is a specific regulatory disclosure about the current voting structure. Given the options, this fits best under the general 'Regulatory Filings' (RNS) as a specific, recurring regulatory disclosure that doesn't match the other specific categories like DVA (which is for *results* of a vote) or SHA (which is for *changes* like splits/issues). However, since it is a mandatory disclosure of share capital structure, it is a highly specific regulatory report. In many contexts, disclosures related to share capital and voting rights are often grouped under general regulatory announcements or specific capital change reports. Since the document is a direct disclosure of the current share count and voting rights, and not an announcement *about* a report, RNS is the most appropriate fallback if a more specific code isn't available. Given the nature of the data (voting rights count), it is a specific regulatory filing.
2025-07-09 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosure of trading in own shares' and explicitly states it is a declaration of purchases of its own shares by Sanofi, including tables detailing transaction dates, volumes, and prices. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-07-07 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions on own shares) and provides a detailed table of share repurchase transactions conducted by Sanofi between June 30, 2025, and July 4, 2025. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2025-07-07 French
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes references to press releases about orphan drug designations but does not contain detailed financial statements or comprehensive financial analysis. The document length is short (1439 characters), and it primarily serves as a regulatory announcement incorporating press releases by reference. According to the rules, such filings that are announcements or regulatory updates without substantive financial data should be classified as Regulatory Filings (RNS).
2025-07-02 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document title is "Déclaration des transactions sur actions propres" (Declaration of transactions on own shares) and it details transactions made by Sanofi on its own stock between June 23, 2025, and June 27, 2025. The content explicitly lists the volume, price, and reason for repurchase ('Raison du Rachat' mentions 'MAR art.5 §2. (a)', which relates to share buyback programs). This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS), which covers company buying back or selling its own shares (share repurchase/issuance).
2025-06-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.